Sandoz Group AG (SDZ.SW)

Swiss: SDZ.SW · 실시간 가격 · USD

73.82

+0.42 (0.57%)

종가 기준: Aug 19, 2026, 10:37 AM

0.57% (1D)

데이터 없음

매수호가	73.76
시가총액	31.92B
매출 (ttm)	11.68B
순이익 (ttm)	646M
베타	0.49
EPS (ttm)	1.2
P/E (ttm)	62.51
선행 P/E	19.96
P/B (ttm)	4.20
P/S (ttm)	2.73
Earnings Date	Feb 17, 2027

매도호가	73.8
거래량	194,412
평균 거래량 (20일)	746,109
시가	73.12
전일 종가	73.40
일중 범위	73.12 - 74.26
52주 범위	43.86 - 75.90
애널리스트	n/a
목표주가	n/a
배당	$0.8 (1.09%)
배당락일	2026년 4월 13일

SDZ.SW 소개

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...

섹터 Healthcare

IPO 일자 Oct 3, 2023

직원 수 20,000

상장 거래소 Swiss

티커 SDZ.SW

웹사이트 https://www.sandoz.com

전체 기업 정보

재무 실적

2025년 Sandoz의 매출은 11.16B로, 전년 10.38B 대비 7.44% 증가했습니다. 순이익은 914M로, undefined% 증가했습니다.

재무 수치 단위: CHF 재무제표

다음 실적 발표

Sandoz Group AG의 실적 발표 예정일은 Feb 17, 2027, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · The Wall Street Journal

Health Care Roundup: Market Talk

Find insights on Sandoz’s deal with Henlius, AstraZeneca and more in the latest Market Talks covering the health care sector.

1일 전 · Pharmaceutical Technology

Sandoz targets industry patent void with $322m Henlius deal

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

1주 전 · GuruFocus.com

Sandoz Group AG (SDZNY) (H1 2026) Earnings Call Highlights: Biosimilar Growth Drives 5% Sales ...

Strong biosimilar performance and strategic launches offset pricing pressures, boosting core EPS by 17%.

1주 전 · The Wall Street Journal

Sandoz in Talks With U.S. Government About Potential Investment, CEO Says

Sandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...

2주 전 · The Wall Street Journal

Sandoz Shares Climb After Biosimilar Sales Drive Growth

Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.

2 페이지 중 1

Sandoz Group AG (SDZ.SW)

SDZ.SW 소개

재무 실적